EP3341011A4 - Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases - Google Patents

Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Download PDF

Info

Publication number: EP3341011A4
Authority: EP; European Patent Office
Prior art keywords: interleukin; receptor; inflammatory diseases; peptide inhibitors; treat inflammatory
Prior art date: 2015-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP16825301.1A

Other languages

German (de)

French (fr)

Other versions

EP3341011A2 (en

Inventor

Ashok Bhandari

Gregory BOURNE

Xiaoli Cheng

Brian Troy FREDERICK

Jie Zhang

Dinesh V. Patel

David Liu

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Protagonist Therapeutics Inc

Original Assignee

Protagonist Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-07-15

Filing date

2016-07-15

Publication date

2019-02-20

2015-07-15 Priority claimed from PCT/US2015/040658 external-priority patent/WO2016011208A1/en

2016-07-15 Application filed by Protagonist Therapeutics Inc filed Critical Protagonist Therapeutics Inc

2018-07-04 Publication of EP3341011A2 publication Critical patent/EP3341011A2/en

2019-02-20 Publication of EP3341011A4 publication Critical patent/EP3341011A4/en

Status Pending legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Hematology (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

EP16825301.1A 2015-07-15 2016-07-15 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases Pending EP3341011A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
PCT/US2015/040658 WO2016011208A1 (en)	2014-07-17	2015-07-15	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US14/800,627 US9624268B2 (en)	2014-07-17	2015-07-15	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US201562264820P	2015-12-08	2015-12-08
US201662281123P	2016-01-20	2016-01-20
PCT/US2016/042680 WO2017011820A2 (en)	2015-07-15	2016-07-15	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Publications (2)

Publication Number	Publication Date
EP3341011A2 EP3341011A2 (en)	2018-07-04
EP3341011A4 true EP3341011A4 (en)	2019-02-20

Family

ID=57757647

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP16825301.1A Pending EP3341011A4 (en)	2015-07-15	2016-07-15	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Country Status (23)

Country	Link
EP (1)	EP3341011A4 (en)
JP (1)	JP6858174B2 (en)
KR (1)	KR102513978B1 (en)
CN (1)	CN108348580B (en)
AU (1)	AU2016293619B2 (en)
BR (1)	BR112018000691A2 (en)
CA (1)	CA2991984A1 (en)
CL (3)	CL2018000128A1 (en)
CO (1)	CO2018000349A2 (en)
CR (1)	CR20180029A (en)
DO (1)	DOP2018000010A (en)
EA (1)	EA035733B9 (en)
EC (1)	ECSP18002929A (en)
HK (2)	HK1257747A1 (en)
IL (1)	IL256827A (en)
MX (1)	MX2018000542A (en)
NI (1)	NI201800008A (en)
PE (1)	PE20180571A1 (en)
PH (1)	PH12018500086A1 (en)
SG (1)	SG10201912066SA (en)
SV (1)	SV2018005614A (en)
UA (1)	UA123772C2 (en)
WO (1)	WO2017011820A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME03300B (en)	2012-06-13	2019-07-20	Incyte Holdings Corp	Substituted tricyclic compounds as fgfr inhibitors
EP4091624A1 (en)	2013-03-15	2022-11-23	Protagonist Therapeutics, Inc.	Hepcidin analogues and uses thereof
ES2657451T3 (en)	2013-04-19	2018-03-05	Incyte Holdings Corporation	Bicyclic heterocyclics as FGFR inhibitors
DK3143037T3 (en)	2014-05-16	2021-09-20	Protagonist Therapeutics Inc	ALPHA4BETA7-INTEGRIN-THIOETHER-PEPTIDE ANTAGONISTS
RU2736637C9 (en)	2014-07-17	2021-02-08	Протагонист Терепьютикс, Инк.	Peptidic interleukin-23 receptor inhibitors for oral administration and use thereof for treating inflammatory intestinal diseases
JP2017535527A (en)	2014-10-01	2017-11-30	プロタゴニストセラピューティクス，インコーポレイテッド	Novel α4β7 peptide monomer and dimer antagonist
WO2016054445A1 (en)	2014-10-01	2016-04-07	Protagonist Therapeutics, Inc.	Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (en)	2015-02-20	2017-12-26	Incyte Corp	BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
ES2751669T3 (en)	2015-02-20	2020-04-01	Incyte Corp	Bicyclic heterocycles as FGFR inhibitors
US10787490B2 (en)	2015-07-15	2020-09-29	Protaganist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
GB2545898B (en)	2015-12-21	2019-10-09	Sutura Therapeutics Ltd	Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
CA3009834A1 (en)	2015-12-30	2017-07-06	Protagonist Therapeutics, Inc.	Analogues of hepcidin mimetics with improved in vivo half lives
US10407468B2 (en)	2016-03-23	2019-09-10	Protagonist Therapeutics, Inc.	Methods for synthesizing α4β7 peptide antagonists
WO2018136646A1 (en) *	2017-01-18	2018-07-26	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AR111960A1 (en)	2017-05-26	2019-09-04	Incyte Corp	CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
GB2563875B (en) *	2017-06-28	2020-08-19	Sutura Therapeutics Ltd	Improvements in drug delivery
CA3073806A1 (en)	2017-09-11	2019-03-14	Protagonist Therapeutics, Inc.	Opioid agonist peptides and uses thereof
WO2019157268A1 (en)	2018-02-08	2019-08-15	Protagonist Therapeutics, Inc.	Conjugated hepcidin mimetics
JP2021523118A (en)	2018-05-04	2021-09-02	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	FGFR inhibitor salt
CR20200590A (en)	2018-05-04	2021-04-26	Incyte Corp	Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020014646A1 (en) *	2018-07-12	2020-01-16	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
CN110015978B (en) *	2019-04-29	2021-03-19	康化（上海）新药研发有限公司	Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
EP3997105A4 (en) *	2019-07-10	2023-09-13	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL291901A (en)	2019-10-14	2022-06-01	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
EP3819307A1 (en) *	2019-11-07	2021-05-12	CytoKi Pharma ApS	Therapeutic derivatives of interleukin-22
JP2023505257A (en)	2019-12-04	2023-02-08	インサイト・コーポレイション	Derivatives of FGFR inhibitors
JP2023505258A (en)	2019-12-04	2023-02-08	インサイト・コーポレイション	Tricyclic heterocycles as FGFR inhibitors
CN118005737A (en)	2020-01-15	2024-05-10	詹森生物科技公司	Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases
CA3202226A1 (en)	2020-11-20	2022-05-27	Janssen Pharmaceutica Nv	Compositions of peptide inhibitors of interleukin-23 receptor
CA3220274A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2023288017A2 (en) *	2021-07-14	2023-01-19	Janssen Biotech, Inc.	Bicyclic peptide inhibitors of interleukin-23 receptor
AU2022402440A1 (en)	2021-12-01	2024-05-30	Zealand Pharma A/S	Peptide inhibitors of interleukin-23 receptor
WO2023172648A2 (en) *	2022-03-09	2023-09-14	Glympse Bio, Inc.	Fluorogenic substrates for aminopeptidase detection in biofluids
CN114751962B (en) *	2022-03-17	2023-11-07	北京大学	Staple peptide, preparation method and pharmaceutical application thereof
WO2024003313A1 (en)	2022-06-30	2024-01-04	Sanofi	New peptides as selective il-23 receptor antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130183755A1 (en) *	2010-03-31	2013-07-18	Grant Gallagher	Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) *	2014-07-17	2016-01-21	Protagonist Therapeutics, Inc.	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5942492A (en) *	1996-11-12	1999-08-24	Angstrom Pharmaceuticals, Inc.	Cyclic peptides that bind to urokinase-type plasminogen activator receptor
MX2009008241A (en)	2007-02-15	2009-10-08	Univ Indiana Res & Tech Corp	Glucagon/glp-1 receptor co-agonists.
US20100190710A1 (en) *	2007-07-06	2010-07-29	Valorisation Hsj, Societe En Commandite	Il-23 receptor antagonists and uses thereof
CA2707840A1 (en)	2007-08-20	2009-02-26	Allozyne, Inc.	Amino acid substituted molecules
US8946150B2 (en)	2011-06-14	2015-02-03	Medical Diagnostic Laboratories, LLC.	Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US9169292B2 (en) *	2011-06-14	2015-10-27	Medical Diagnostic Laboratories, Llc	Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
WO2015054500A2 (en) *	2013-10-09	2015-04-16	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines

2016
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en active Pending
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/en active Search and Examination
- 2016-07-15 UA UAA201801482A patent/UA123772C2/en unknown
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 EA EA201890325A patent/EA035733B9/en not_active IP Right Cessation
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/en active IP Right Grant
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/en unknown
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/en active Active
- 2016-07-15 MX MX2018000542A patent/MX2018000542A/en unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en active Application Filing
- 2016-07-15 CR CR20180029A patent/CR20180029A/en unknown
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/en active Active
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/en unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/en unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/en unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/en unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/en unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/en unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/en unknown
2019
- 2019-01-04 HK HK19100122.0A patent/HK1257747A1/en unknown
- 2019-01-23 HK HK19101174.5A patent/HK1259149A1/en unknown
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/en unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130183755A1 (en) *	2010-03-31	2013-07-18	Grant Gallagher	Therapeutic application of isolated naturally-occurring soluble truncated forms of il-23 receptor
WO2016011208A1 (en) *	2014-07-17	2016-01-21	Protagonist Therapeutics, Inc.	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017011820A2 *

Also Published As

Publication number	Publication date
CN108348580B (en)	2022-05-10
CL2018000128A1 (en)	2018-06-15
CR20180029A (en)	2018-06-05
IL256827A (en)	2018-03-29
PH12018500086A1 (en)	2018-07-30
KR102513978B1 (en)	2023-03-27
JP2018522008A (en)	2018-08-09
WO2017011820A2 (en)	2017-01-19
CL2021000343A1 (en)	2021-08-06
CN108348580A (en)	2018-07-31
AU2016293619B2 (en)	2021-02-25
KR20180030663A (en)	2018-03-23
EA035733B1 (en)	2020-07-31
CL2018003322A1 (en)	2019-01-18
EA035733B9 (en)	2021-01-14
CA2991984A1 (en)	2017-01-19
ECSP18002929A (en)	2018-03-31
MX2018000542A (en)	2018-06-27
PE20180571A1 (en)	2018-04-04
DOP2018000010A (en)	2018-03-30
JP6858174B2 (en)	2021-04-14
SV2018005614A (en)	2018-05-22
UA123772C2 (en)	2021-06-02
WO2017011820A3 (en)	2017-02-23
HK1257747A1 (en)	2019-10-25
BR112018000691A2 (en)	2018-09-18
SG10201912066SA (en)	2020-02-27
CO2018000349A2 (en)	2018-07-10
EP3341011A2 (en)	2018-07-04
EA201890325A1 (en)	2018-06-29
NI201800008A (en)	2018-06-29
HK1259149A1 (en)	2019-11-29
AU2016293619A1 (en)	2018-02-01

Legal Events

Date	Code	Title	Description
2017-01-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-06-01	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-06-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2018-07-04	17P	Request for examination filed	Effective date: 20180212
2018-07-04	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2018-07-04	AX	Request for extension of the european patent	Extension state: BA ME
2018-10-24	DAV	Request for validation of the european patent (deleted)
2018-10-24	DAX	Request for extension of the european patent (deleted)
2019-02-20	A4	Supplementary search report drawn up and despatched	Effective date: 20190121
2019-02-20	RIC1	Information provided on ipc code assigned before grant	Ipc: C07K 7/08 20060101ALI20190115BHEP Ipc: A61K 38/20 20060101AFI20190115BHEP Ipc: C07K 14/54 20060101ALI20190115BHEP Ipc: C07K 7/06 20060101ALI20190115BHEP
2019-10-25	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1257747 Country of ref document: HK
2020-02-10	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2020-03-18	17Q	First examination report despatched	Effective date: 20200213
2020-10-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-02-24	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2021-04-28	RAP3	Party data changed (applicant data changed or rights of an application transferred)	Owner name: PROTAGONIST THERAPEUTICS, INC.
2023-06-21	P01	Opt-out of the competence of the unified patent court (upc) registered	Effective date: 20230515

Publication	Publication Date	Title
HK1259149A1 (en)	2019-11-29	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL285614A (en)	2021-09-30	Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
EP3570864A4 (en)	2020-12-30	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3820883A4 (en)	2022-04-20	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
IL253796A0 (en)	2017-09-28	Therapeutically active compounds and their methods of use
IL251246A0 (en)	2017-05-29	Therapeutically active compounds and their methods of use
EP3151833A4 (en)	2018-01-10	Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
IL250318B (en)	2020-05-31	Protein kinase c inhibitors and methods of their use
EP3047024A4 (en)	2017-05-03	Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders
IL253118A0 (en)	2017-08-31	Methods of treating inflammatory diseases
EP3116898A4 (en)	2017-08-30	Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
HK1211471A1 (en)	2016-05-27	Treating th2-mediated diseases by inhibition of bromodomain- comprising proteins brd7 and brd9 brd7 brd9 th2
HK1252037A1 (en)	2019-05-10	Methods of treating inflammatory diseases
IL289628A (en)	2022-03-01	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
EP3157531A4 (en)	2018-05-16	Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same
EP3503903A4 (en)	2020-03-25	Ascaroside treatment of autoimmune and inflammatory diseases
EP3148575A4 (en)	2018-01-24	Methods and compositions for treating allergy and inflammatory diseases
EP3408413A4 (en)	2019-08-28	Prediction of therapeutic response in inflammatory conditions
EP3288379A4 (en)	2018-10-24	Peptide compositions and methods of use
DK3229827T3 (en)	2019-12-09	MODIFIED PEPTIDES AND ITS APPLICATION FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES
EP3393460A4 (en)	2019-09-25	Compositions and methods of treatment for mvid and related diseases
EP3313427A4 (en)	2018-12-26	Therapeutic peptides and methods of use thereof
EP3139944A4 (en)	2017-10-11	Use of peptide for treating angiogenesis-related diseases
IL241934A (en)	2017-11-30	Inhibitory peptides for the treatment of inflammatory diseases
EP3534932A4 (en)	2020-09-09	Treatment of diseases related to igfb3 and its receptor